ArticleJoint bone spine2018
Treatment and outcomes in patients with IgG4-related disease using the IgG4 responder index.
Article in Joint bone spine, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 30 citations in OpenAlex.
- Azathioprine as maintenance therapy for IgG4-related diseases: a retrospective case series and case-based review of the literature.Rheumatology international · 2026Review
- Comparison of Efficacy and Safety of Different Medication Protocols in Patients with Immunoglobulin G4-Related Disease Based on Follow-up Time: A Systematic Review and Network Meta-analysis.Archives of rheumatology · 2026Article
- New Developments in the Treatment of IgG4-Related Disease: A Comprehensive Clinical Approach.Journal of clinical medicine · 2025Review
- MRI diagnosis of tumor‑like IgG4 masses in bilateral distal ureters: A case report.Experimental and therapeutic medicine · 2023Article
- Co-occurrence of IgA nephropathy and IgG4-Tubulointersitial nephritis effectively treated with tacrolimus: a case report.BMC nephrology · 2021Article
- Response to Treatment in IgG4-Related Disease Assessed by Quantitative PET/CT Scan.Clinical nuclear medicine · 2021Article
- Debulking Surgery Combined with Low-Dose Oral Prednisolone and Azathioprine for Intractable IgG4-Related Orbital Disease: A Case Report.Medicina (Kaunas, Lithuania) · 2021Article
- A Follow-Up Study of a European IgG4-Related Disease Cohort Treated with Rituximab.Journal of clinical medicine · 2021Article
- Allergic Aspects of IgG4-Related Disease: Implications for Pathogenesis and Therapy.Frontiers in immunology · 2021Review
- Non-tuberculous, adenosine deaminase-positive lymphocytic pleural effusion: Consider immunoglobulin G4-related disease.Sarcoidosis, vasculitis, and diffuse lung diseases : official journal of WASOG · 2020Article
- Clinical features and outcomes in a cohort of patients with immunoglobulin G4-related disease at a university hospital in Spain.Clinical kidney journal · 2019Article
- Clinical significance of IgG4 in sinonasal and skull base inflammatory pseudotumor.European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery · 2019Article
- Retrospective single-centre analysis of IgG4-related disease patient population and treatment outcomes between 2007 and 2017.Rheumatology advances in practice · 2019Article
- A Case of IgG4-Related Kidney Disease Developing While on Steroid Treatment for Autoimmune IgG4 Pancreatitis.Journal of investigative medicine high impact case reportsArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors at 10 institutions in 3 countries.
Funding
Abstract
backgroundIgG4-related disease (IgG4-RD) is an autoimmune disease triggering an inflammatory cascade that leads to fibrosis. Outcome measures are limited and treatment options remain underexplored.
objectivesTo assess the variation of the IgG4 responder index (IgG4-RI) in a cohort of IgG4-RD patients and to explore their treatments and outcomes.
methodsWe studied the clinical phenotype, severity of the disease and response to treatment in an ambispective multicenter cohort study including 14 different hospitals in Spain. All patients met the 2012 international consensus on pathology criteria for diagnosis.
resultsSixty-eight patients were included, with a mean age of 53.4 years and predominance of male sex. The most commonly involved tissues were: retroperitoneum (33%), orbital pseudotumor (28%) and maxillary and paranasal sinuses (24%). IgG4-RI values were higher in patients with multiorgan disease and before treatment. After being treated, IgG4-RI values were lower, in accordance with the high rates of treatment response. Most patients received: glucocorticoids (GC), surgery, azathioprine (AZA), mofetil mycophenolate or rituximab. GC alone, GC plus surgery and GC plus AZA were given in the most of the IgG4-RD disease activity episodes. All treatments had high response rates but relapses and flares were common.
conclusionsIgG4-RI is a promising outcome measure in IgG4-RD, but still in development. Treatment algorithms are ill defined. GC and rituximab are the drugs with more evidence available. Disease modifying anti-rheumatic drugs may have a role in IgG4-RD and warrant more prospective studies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.